CoChat

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

Open access

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

Therapies inhibiting receptor tyrosine kinases (RTKs) are effective against some human cancers when they lead to simultaneous downregulation of PI3K/AKT and MEK/ERK signaling. However, mutant KRAS has the capacity to directly activate ERK and PI3K signaling, and this is thought to underlie the resistance of KRAS mutant cancers to RTK inhibitors. Here, we have elucidated the molecular regulation of both the PI3K/AKT and MEK/ERK signaling pathways in KRAS mutant colorectal cancer cells and identified combination therapies that lead to robust cancer cell apoptosis. KRAS knockdown using shRNA suppressed ERK signaling in all of the human KRAS mutant colorectal cancer cell lines examined. However, no decrease, and actually a modest increase, in AKT phosphorylation was often seen. By performing PI3K immunoprecipitations, we determined that RTKs, often IGF-IR, regulated PI3K signaling in the KRAS mutant cell lines. This conclusion was also supported by the observation that specific RTK inhibition led to marked suppression of PI3K signaling and biochemical assessment of patient specimens. Interestingly, combination of RTK and MEK inhibitors led to concomitant inhibition of PI3K and MEK signaling, marked growth suppression, and robust apoptosis of human KRAS mutant colorectal cancer cell lines in vitro and upon xenografting in mice. These findings provide a framework for utilizing RTK inhibitors in the treatment of KRAS mutant colorectal cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci57909

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Research works printed but not linked: 2

  1. Yakes, 2002, Cancer Res., 62, 4132
  2. Guix, 2008, J Clin Invest., 118, 2609

Cited by

See all 215

Metadata

Authors
Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., Wong, K.-K., Cantley, L. C., & Engelman, J. A.
Affiliations
  • Massachusetts General Hospital (US)
  • Harvard University (US)
  • Beth Israel Deaconess Medical Center (US)
Corresponding author
Engelman, Jeffrey A.
Venue
Journal of Clinical Investigation
Published
2011-11-01
Volume
121
Issue
11
Pages
4311-4321
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2030733555
Cited by
210
References
56
Citations by year
2026: 4 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 8 · 2021: 18 · 2020: 19 · 2019: 16 · 2018: 11 · 2017: 21 · 2016: 16 · 2015: 12 · 2014: 26 · 2013: 23 · 2012: 19
FWCI
8.84
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Association for Cancer Research
  • V Foundation for Cancer Research
  • Uniting Against Lung Cancer
  • Brigham and Women's Hospital
  • Massachusetts General Hospital
  • Kanae Foundation for the Promotion of Medical Science
  • National Institutes of Health
  • National Cancer Institute (P50CA127003, U01CA141457, RC2CA147940, R01CA122794, R01CA140594, CA127003, P50CA090578, K08CA120060, K99CA149169, CA120060-01, R01CA137181, R01CA137008)
  • National Institute of General Medical Sciences (R01-GM41890, R01GM041890)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
receptor tyrosine kinase, PI3K/Akt signaling, MEK/ERK signaling, KRAS mutation, colorectal cancer, receptor tyrosine kinase inhibitors, IGF-1 receptor, combination therapy, MEK inhibitors, apoptosis, drug resistance, Akt phosphorylation
MeSH terms
Animals, Base Sequence, Humans, Male, Mice, Nude, Mutation, Neoplasm Transplantation, Proto-Oncogene Proteins, Transplantation, Heterologous, Colorectal Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Apoptosis, DNA Primers, ras Proteins, Phosphatidylinositol 3-Kinases, Receptor Protein-Tyrosine Kinases, MAP Kinase Signaling System, RNA, Small Interfering, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-akt, Mice, Gene Knockdown Techniques, Class I Phosphatidylinositol 3-Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. https://app.cochat.ai/papers/10.1172/jci57909
The paper
Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., Wong, K.-K., Cantley, L. C., & Engelman, J. A. (2011). Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. Journal of Clinical Investigation. https://doi.org/10.1172/jci57909

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.